Nasdaq

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations. ALISO VIEJO, Calif., Jan. 12, 2021 /PRNewswire/ -- MicroVention, Inc., a U.S.-based ...
La Grande Observer

Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment

ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of ...
Business Wire

MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

SAN DIEGO & ALISO VIEJO, Calif.--(BUSINESS WIRE)--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of WEB-IT 5-year ...
Nasdaq

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo Corporation’s (TRUMY) wholly-owned subsidiary MicroVention, Inc. recently announced the publication of the Clinical Evaluation of WEB 17 Device in Intracranial Aneurysms (CLEVER) study results.
Longview News-Journal

Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment

The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that ...